Neisseria meningitidis is a Gram-negative microorganism that exists exclusively in humans
and can cause devastating invasive disease. Although capsular polysaccharide-based …

Neisseria meningitidis is a leading cause of meningitis and sepsis worldwide. The first broad-
spectrum multicomponent vaccine against serogroup B meningococcus (MenB), 4CMenB …

Mapping of epitopes recognized by functional monoclonal antibodies (mAbs) is essential for
understanding the nature of immune responses and designing improved vaccines …

Certain pathogens recruit host complement inhibitors such as factor H (fH) to evade the
immune system. Microbial complement inhibitor-binding molecules can be promising …

There is currently no comprehensive meningococcal vaccine, due to difficulties in
immunizing against organisms expressing serogroup B capsules. To address this problem …

Meningococcal factor H binding protein (fHbp) is a promising vaccine antigen that binds the
human complement downregulatory molecule factor H (fH), and this binding enhances the …

Meningococcal vaccines containing factor H binding protein (fHbp) are in clinical
development. fHbp binds human fH, which enables the meningococcus to resist …

We compared the bactericidal activity of recombinant sets of chimeric IgG monoclonal
antibodies against two important outer membrane meningococcal vaccine antigens: PorA …

Binding of the complement-downregulating protein factor H (fH) to the surface of the
meningococcus is important for survival of the organism in human serum. The …

The first cross‐protective Neisseria meningitidis vaccine (focus on serogroup B), the protein‐
based 4 component meningococcus serogroup B (4CMenB), includes the New Zealand …